The sooner you know you have breast cancer, the sooner you can start treatment. And the prognosis for treatment is always better if it is detected early. Reason enough for Peter Westerink, managing director of IDS International B.V. (IDS), to work on the development of BreasTel®, an innovative tool for breast screening.
Peter worked in the medical industry for many years and has a background in radiology. In 2014, he decided to set up a company to help medical start-ups successfully bring their innovative ideas to fruition. One of those start-ups is IDS, which is currently developing BreasTel®.
Operation and use
How exactly does BreasTel® work? Peter explains. “It is an innovative tool that supports breast (self-)examination. It automatically distinguishes between benign and suspicious lumps in the breast that may indicate breast cancer. BreasTel® is easy to use: you connect it to a smartphone, tablet or computer. It is a handheld device that you hold against the breast at the site of the palpable lump.”
It assists primary care providers, such as GPs, in characterising the palpable lump in the breast. “BreasTel® provides an indication of ‘benign’ or ‘suspicious’, meaning that if the lump is identified as benign, women can be reassured much earlier in the process. Alternatively, if the indication is suspicious, women can be referred immediately for further investigation at hospital.”
For self-examination
“It is not only healthcare professionals who benefit from BreasTel®; the aim is also for women to be able to use it at home in the long term. BreasTel® provides an automated result, meaning you do not need medical expertise to interpret it.”
For IDS, providing reassurance, reducing unnecessary referrals and tests, and the early detection of breast cancer are the most important factors. “Ultimately, you want breast cancer to be detected earlier. Because the sooner you know, the sooner you can start treatment.” And that often has a positive effect on the outcome of treatment.
“There is also a financial aspect: research shows that of the women referred to hospital by GPs, around 90 per cent ultimately turn out not to have cancer. An earlier referral therefore not only enables us to reassure women sooner, but also helps to reduce many unnecessary tests and costs.”
Prototype further development
Where does IDS stand now? "A prototype has been developed and tested," Peter explains. "The research has demonstrated how BreasTel® works and the tests have shown what technological adjustments are still needed to make it market-ready." For this development, IDS still needs funding.
Cooperation within Lifeport
Peter attended several workshops organised by Briskr Health & High Tech, which supports start-ups and helps them grow. “I got to know them through the regional development agency OostNL and really appreciate the help they offer together with the Briskr partners.”
At the end of last year, Peter, along with three other entrepreneurs, was selected by OostNL and Briskr to pitch to the BANN (Business Angels Network Nijmegen) with a view to securing funding. Discussions and contacts with the BANN investors are still ongoing. There is a great deal of interest in the BreasTel innovation from the Arnhem-Nijmegen region.
Radboudumc collaborated on the clinical trial involving the BreasTel® prototype. Here too, support and assistance were provided for the development of BreasTel®.
More than breast cancer?
“I hope that in future we will be able to apply this technology to a wider range of conditions. Because the earlier cancer is detected, the better the prognosis and the chances of recovery.”
This article was previously published in a slightly different form on Briskr.nl


